{"entity":{"edinet_code":"E36190","sec_code":"4887","name_ja":"サワイグループホールディングス株式会社","name_en":"SAWAI GROUP HOLDINGS Co., Ltd.","industry":"医薬品","industry_en":"Pharmaceutical"},"names_note":"English company names are as filed: each company's own annual report states its English name on the cover page. For a company that files no annual report, EDINET's filer registry is used instead. The as-filed Japanese name is always returned alongside.","filing":{"doc_id":"S100YITS","filer_name":"サワイグループホールディングス株式会社","filer_name_en":"SAWAI GROUP HOLDINGS Co., Ltd.","period_end":"2026-03-31","filed_date":"2026-06-24","sha256":"d5a597ab9306323a4090d4b81e36c5e1436e44582ebe1f3b90651985aac45e35","status":"partial"},"basis":{"measurement":"carrying_amount","entity_scope":"holdco_consolidated","share_scope":"both","trust_included":"unknown","as_of":"2026-03-31","period_type":"annual","labels":{"measurement":"Balance-sheet carrying amount. Under Japanese GAAP listed equities are carried at market with the valuation difference in other comprehensive income, so carrying amount and acquisition cost diverge enormously on positions bought decades ago.","entity_scope":"Every disclosing entity in the filing, summed — the reporting company plus each group holder it names.","share_scope":"Listed and unlisted shares together.","trust_included":"The filing does not state whether retirement-benefit-trust shares are included. Never guessed — shares contributed to such a trust leave the holder's balance sheet while the settlor normally keeps the right to instruct the vote.","period_type":"From an annual securities report (有価証券報告書). The policy shareholding table appears only in the annual report."},"not_comparable":"Figures are balance-sheet CARRYING AMOUNT at fiscal year end, from the annual securities report. They are NOT comparable with the acquisition-cost or book-value-reduction figures quoted in press coverage and IR presentations, and NOT comparable with interim (half-year) figures, which this product does not hold. Always state the basis with the number, and use check_claim before setting one of our figures against a published one."},"basis_note":"The basis every yen figure on this response is on. entity_scope is read from the filing's own disclosing entities, not assumed: scale_entities and flows each carry their own entity_scope and share_scope, and a figure quoted for one entity is not the group figure.","holdings":[{"holder_table":"largest","held_name_raw":"株式会社メディパルホールディングス","held_name_en":"MEDIPAL HOLDINGS CORPORATION","held_sec_code":"7459","match_status":"matched","shares":218100,"book_value_yen":641000000,"prior_shares":218100,"prior_book_value_yen":509000000,"purpose_ja":"有力医薬品卸として良好な関係を維持していくことの重要性を考慮して保有しております。なお、定期的に定量的な保有効果を検証しております。","reciprocal":"有","pct_outstanding":0.1065468719621501,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.3589910168238536,"pct_of_holder_assets":0.17809562707164667,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":178556000000,"holder_total_assets_yen":359919000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"largest","held_name_raw":"アルフレッサ ホールディングス株式会社","held_name_en":"Alfresa Holdings Corporation","held_sec_code":"2784","match_status":"matched","shares":224000,"book_value_yen":566000000,"prior_shares":224000,"prior_book_value_yen":473000000,"purpose_ja":"有力医薬品卸として良好な関係を維持していくことの重要性を考慮して保有しております。なお、定期的に定量的な保有効果を検証しております。","reciprocal":"有","pct_outstanding":0.12294027023808152,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.31698738771029816,"pct_of_holder_assets":0.1572576051833885,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":178556000000,"holder_total_assets_yen":359919000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"Neurolief Ltd.","held_name_en":null,"held_sec_code":null,"match_status":"foreign","shares":595751,"book_value_yen":400000000,"prior_shares":595751,"prior_book_value_yen":374000000,"purpose_ja":"株式購入先企業において現在進行中の新規事業案件の更なる進展のため保有しております。なお、定期的に定量的な保有効果を検証しております。","reciprocal":"無","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":null,"pct_share_classes":null,"pct_of_holder_equity":0.22401935527229552,"pct_of_holder_assets":0.11113611673737703,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":178556000000,"holder_total_assets_yen":359919000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"largest","held_name_raw":"ダイト株式会社","held_name_en":"Daito Pharmaceutical Co.,Ltd.","held_sec_code":"4577","match_status":"matched","shares":193600,"book_value_yen":280000000,"prior_shares":96800,"prior_book_value_yen":212000000,"purpose_ja":"製品製造に関する委受託契約先として良好な関係を維持していくことの重要性を考慮して保有しております。なお、定期的に定量的な保有効果を検証しております。また、当事業年度中に株式分割が行われたことにより株式数が増加しております。","reciprocal":"有","pct_outstanding":0.6713322408002169,"pct_unavailable":null,"pct_basis_period_end":"2026-05-31","pct_share_classes":1,"pct_of_holder_equity":0.15681354869060687,"pct_of_holder_assets":0.07779528171616391,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":178556000000,"holder_total_assets_yen":359919000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":["share split"],"note_refs":[],"share_ratio":2.0,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"サスメド株式会社","held_name_en":"SUSMED,Inc.","held_sec_code":"4263","match_status":"matched","shares":245000,"book_value_yen":236000000,"prior_shares":245000,"prior_book_value_yen":145000000,"purpose_ja":"同社のデジタルヘルスケア領域での技術や知見を当社グループの事業と融合させた協業の展開について検討を進めるため保有しております。なお、定期的に定量的な保有効果を検証しております。","reciprocal":"無","pct_outstanding":1.4529797946850591,"pct_unavailable":null,"pct_basis_period_end":"2026-06-30","pct_share_classes":1,"pct_of_holder_equity":0.13217141961065437,"pct_of_holder_assets":0.06557030887505244,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":178556000000,"holder_total_assets_yen":359919000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"largest","held_name_raw":"株式会社テクノ菱和","held_name_en":"TECHNO RYOWA LTD.","held_sec_code":"1965","match_status":"matched","shares":31460,"book_value_yen":182000000,"prior_shares":31460,"prior_book_value_yen":83000000,"purpose_ja":"主要設備メンテナンス取引先として良好な関係を維持していくことの重要性を考慮して保有しております。なお、定期的に定量的な保有効果を検証しております。","reciprocal":"有","pct_outstanding":0.15212174536347814,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.10192880664889446,"pct_of_holder_assets":0.05056693311550654,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":178556000000,"holder_total_assets_yen":359919000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"largest","held_name_raw":"朝日印刷株式会社","held_name_en":"ASAHI PRINTING CO.,LTD.","held_sec_code":"3951","match_status":"matched","shares":165200,"book_value_yen":144000000,"prior_shares":165200,"prior_book_value_yen":149000000,"purpose_ja":"添付文書等の発注先として良好な関係を維持していくことの重要性を考慮して保有しております。なお、定期的に定量的な保有効果を検証しております。","reciprocal":"有","pct_outstanding":0.7986799927616,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.08064696789802639,"pct_of_holder_assets":0.04000900202545573,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":178556000000,"holder_total_assets_yen":359919000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"largest","held_name_raw":"株式会社メディカル一光グループ","held_name_en":"Medical Ikkou Group Co.,Ltd.","held_sec_code":"3353","match_status":"matched","shares":50000,"book_value_yen":142000000,"prior_shares":140000,"prior_book_value_yen":327000000,"purpose_ja":"有力医薬品卸として良好な関係を維持していくことの重要性を考慮して保有しております。なお、定期的に定量的な保有効果を検証しております。また、当事業年度において一部の株式を売却しております。","reciprocal":"有","pct_outstanding":1.327703868929074,"pct_unavailable":null,"pct_basis_period_end":"2026-02-28","pct_share_classes":1,"pct_of_holder_equity":0.07952687112166491,"pct_of_holder_assets":0.03945332144176884,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":178556000000,"holder_total_assets_yen":359919000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"largest","held_name_raw":"株式会社三菱ＵＦＪフィナンシャル・グループ","held_name_en":"Mitsubishi UFJ Financial Group, Inc.","held_sec_code":"8306","match_status":"matched","shares":15600,"book_value_yen":41000000,"prior_shares":15600,"prior_book_value_yen":31000000,"purpose_ja":"主要取引金融機関として良好な関係を維持していくことの重要性を考慮して保有しております。なお、定期的に定量的な保有効果を検証しております。","reciprocal":"無(※)","pct_outstanding":0.000138097724663646,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.02296198391541029,"pct_of_holder_assets":0.011391451965581145,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":178556000000,"holder_total_assets_yen":359919000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"largest","held_name_raw":"株式会社三井住友フィナンシャルグループ","held_name_en":"Sumitomo Mitsui Financial Group, Inc.","held_sec_code":"8316","match_status":"matched","shares":4500,"book_value_yen":23000000,"prior_shares":4500,"prior_book_value_yen":17000000,"purpose_ja":"主要取引金融機関として良好な関係を維持していくことの重要性を考慮して保有しております。なお、定期的に定量的な保有効果を検証しております。","reciprocal":"無(※)","pct_outstanding":0.00011788005020663273,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.012881112928156992,"pct_of_holder_assets":0.006390326712399179,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":178556000000,"holder_total_assets_yen":359919000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"largest","held_name_raw":"株式会社みずほフィナンシャルグループ","held_name_en":"Mizuho Financial Group, Inc.","held_sec_code":"8411","match_status":"matched","shares":1810,"book_value_yen":11000000,"prior_shares":1810,"prior_book_value_yen":7000000,"purpose_ja":"主要取引金融機関として良好な関係を維持していくことの重要性を考慮して保有しております。なお、定期的に定量的な保有効果を検証しております。","reciprocal":"無(※)","pct_outstanding":7.412582126894844e-05,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.006160532269988127,"pct_of_holder_assets":0.003056243210277868,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":178556000000,"holder_total_assets_yen":359919000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false}],"holders":[{"holder_name":"株式会社テクノ菱和","holder_name_en":"TECHNO RYOWA LTD.","holder_sec_code":"1965","doc_id":"S100YF2U","period_end":"2026-03-31","holder_table":"reporting","shares":211600,"book_value_yen":467000000,"prior_shares":210645,"prior_book_value_yen":417000000,"purpose_ja":"設備工事業の取引先である発行会社グループとの取引関係の維持・強化が当社の企業価値向上に資すると判断し、保有しております。(株式数が増加した理由)事業関係のより一層の強化が当社の企業価値向上に資すると判断し、取引先持株会を通じた購入を行い増加しております。","reciprocal":"無","pct_outstanding":0.18322624829960457,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.7038326475863212,"pct_of_holder_assets":0.462981322123964,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":66351000000,"holder_total_assets_yen":100868000000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"アステナホールディングス株式会社","holder_name_en":"Astena Holdings Co., Ltd.","holder_sec_code":"8095","doc_id":"S100XN2T","period_end":"2025-11-30","holder_table":"reporting","shares":198000,"book_value_yen":392000000,"prior_shares":198000,"prior_book_value_yen":430000000,"purpose_ja":"定量的な保有効果の記載は困難ですが、主にファインケミカル事業における取引先であり、良好な関係の維持、強化を図るために保有しております。信頼関係の構築・維持強化の必要性や事業上の取引状況等に基づく保有意義、同社との取引関係等による経済合理性について経営陣が定期的に検証・審議を行い、保有の合理性があると判断しております。","reciprocal":"無","pct_outstanding":0.17144989207618952,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":1.430813592729131,"pct_of_holder_assets":0.5196113519173924,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":27397000000,"holder_total_assets_yen":75441000000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"アルフレッサホールディングス株式会社","holder_name_en":"Alfresa Holdings Corporation","holder_sec_code":"2784","doc_id":"S100YH29","period_end":"2026-03-31","holder_table":"reporting","shares":165000,"book_value_yen":364000000,"prior_shares":165000,"prior_book_value_yen":326000000,"purpose_ja":"・良好な取引関係の維持発展・当社グループの取引先・検証実施(注)１","reciprocal":"無(注)３","pct_outstanding":0.14287491006349126,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.07166722779743376,"pct_of_holder_assets":0.024153691798892644,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":507903000000,"holder_total_assets_yen":1507016000000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"朝日印刷株式会社","holder_name_en":"ASAHI PRINTING CO.,LTD.","holder_sec_code":"3951","doc_id":"S100YEXW","period_end":"2026-03-31","holder_table":"reporting","shares":149400,"book_value_yen":330000000,"prior_shares":149400,"prior_book_value_yen":296000000,"purpose_ja":"医薬品パッケージ等の取引先であり、安定的・長期的な取引関係の維持・強化を目的に保有しております。定量的な保有効果については秘密保持の観点から記載しておりませんが、保有意義や取引状況、経済合理性を取締役会において検証し、保有の合理性があると判断しております。","reciprocal":"―（注）","pct_outstanding":0.12936673674839755,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.898325847284606,"pct_of_holder_assets":0.47705095771593786,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":36735000000,"holder_total_assets_yen":69175000000,"implausible":false,"reciprocal_held_both_ways":null},{"holder_name":"株式会社メディパルホールディングス","holder_name_en":"MEDIPAL HOLDINGS CORPORATION","holder_sec_code":"7459","doc_id":"S100YI1C","period_end":"2026-03-31","holder_table":"reporting","shares":146400,"book_value_yen":323000000,"prior_shares":146400,"prior_book_value_yen":290000000,"purpose_ja":"・当社グループの医療用医薬品等卸売事業の商品の仕入等における良好な取引関係の維持・強化のため、保有しております。・定量的な保有効果については、（注）１に記載しております。","reciprocal":"有","pct_outstanding":0.12676901111087954,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.040608549922743174,"pct_of_holder_assets":0.01680539354277467,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":795399000000,"holder_total_assets_yen":1922002000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"株式会社メディカル一光グループ","holder_name_en":"Medical Ikkou Group Co.,Ltd.","holder_sec_code":"3353","doc_id":"S100Y4Y9","period_end":"2026-02-28","holder_table":"reporting","shares":96677,"book_value_yen":224387000,"prior_shares":89390,"prior_book_value_yen":170467000,"purpose_ja":"保有目的は、取引先との関係強化であります。株式が増加した理由は、取引先持株会に加入しており、定期投資により増加しております。","reciprocal":"有","pct_outstanding":0.08371344048610997,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":1.3733620148412482,"pct_of_holder_assets":0.5971532396495359,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":16338518000,"holder_total_assets_yen":37576117000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"ダイト株式会社","holder_name_en":"Daito Pharmaceutical Co.,Ltd.","holder_sec_code":"4577","doc_id":"S100YYNI","period_end":"2026-05-31","holder_table":"reporting","shares":57600,"book_value_yen":100000000,"prior_shares":57600,"prior_book_value_yen":102000000,"purpose_ja":"(保有目的) 当社の原薬及び製剤の販売先であり、取引関係の維持・強化を目的として保有しております。","reciprocal":"無(注２)","pct_outstanding":0.049876332240346044,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.18890022290226302,"pct_of_holder_assets":0.1364424008404852,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":52938000000,"holder_total_assets_yen":73291000000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"株式会社日立物流","holder_name_en":"LOGISTEED, Ltd.","holder_sec_code":"9086","doc_id":"S100OB3P","period_end":"2022-03-31","holder_table":"reporting","shares":20000,"book_value_yen":89000000,"prior_shares":20000,"prior_book_value_yen":107000000,"purpose_ja":"中長期的な成長・企業価値向上のため継続保有2021年度国内連結売上収益５億円(年累計)以上","reciprocal":"無","pct_outstanding":0.045671444333622684,"pct_unavailable":null,"pct_basis_period_end":"2022-03-31","pct_share_classes":1,"pct_of_holder_equity":0.05230064053593465,"pct_of_holder_assets":0.011239105013651093,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":170170000000,"holder_total_assets_yen":791878000000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"コーア商事ホールディングス株式会社","holder_name_en":"KOA SHOJI HOLDINGS CO.,LTD.","holder_sec_code":"9273","doc_id":"S100Z2Z6","period_end":"2026-06-30","holder_table":"largest","shares":44977,"book_value_yen":75787000,"prior_shares":43869,"prior_book_value_yen":80413000,"purpose_ja":"販売先との長期的な取引と取引拡大を継続する目的で保有(含む持株会）しております。増加理由は持株会を通じた取得によるものであります。","reciprocal":"無","pct_outstanding":0.038945968666216045,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.2430599843125654,"pct_of_holder_assets":0.19170706991754424,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":31180369000,"holder_total_assets_yen":39532710000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"セコム株式会社","holder_name_en":"SECOM CO., LTD.","holder_sec_code":"9735","doc_id":"S100YICV","period_end":"2026-03-31","holder_table":"reporting","shares":30000,"book_value_yen":66000000,"prior_shares":30000,"prior_book_value_yen":59000000,"purpose_ja":"主にセキュリティサービス事業におけるサービスおよび商品の取引等、取引関係の維持拡大を目的に保有しております。定量的な保有効果は個別の取引条件等に関わるため記載しておりませんが、(1)に記載の方法で2025年10月に保有の妥当性の検証を行いました。","reciprocal":"無","pct_outstanding":0.02597725637518023,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.004400932997795533,"pct_of_holder_assets":0.0029594727116437763,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":1499682000000,"holder_total_assets_yen":2230127000000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"株式会社バイタルケーエスケー・ホールディングス","holder_name_en":"VITAL KSK HOLDINGS,INC.","holder_sec_code":"3151","doc_id":"S100YDSN","period_end":"2026-03-31","holder_table":"largest","shares":6000,"book_value_yen":13000000,"prior_shares":6000,"prior_book_value_yen":11000000,"purpose_ja":"①商品の確保や仕入の円滑化のため　②該当なし　③ＡがＢを上回っております　④該当なし","reciprocal":"無","pct_outstanding":0.005195451275036046,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.010951333956716958,"pct_of_holder_assets":0.004055301839235357,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":118707000000,"holder_total_assets_yen":320568000000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"日医工株式会社","holder_name_en":"Nichi-Iko Pharmaceutical Co., Ltd.","holder_sec_code":"4541","doc_id":"S100OLZH","period_end":"2022-03-31","holder_table":"reporting","shares":200,"book_value_yen":0,"prior_shares":200,"prior_book_value_yen":1000000,"purpose_ja":"(保有目的)当社とは医薬品の製造委受託関係があり、事業上の関係の維持・強化を目的として保有しております。","reciprocal":"無","pct_outstanding":0.0004567144433362268,"pct_unavailable":null,"pct_basis_period_end":"2022-03-31","pct_share_classes":1,"pct_of_holder_equity":0.0,"pct_of_holder_assets":0.0,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":13394000000,"holder_total_assets_yen":260559000000,"implausible":false,"reciprocal_held_both_ways":false}],"reclassified":[],"reclassified_note":"As filed, from the annual report's 保有目的を変更した投資株式 table. direction=to_pure means the filer moved the holding from a policy shareholding to 純投資目的 (pure investment); the shares are not necessarily sold, and the position leaves the named policy table in the year of the change. direction=to_policy is the reverse. fy_of_change_ja is the fiscal year the filer states the change took effect, verbatim — some filers list more than one. A filing repeats these rows for several years after the change, so this is a standing disclosure, not a one-year event.","implausible_note":"A row is flagged implausible when its two filed numbers are mutually impossible — book value ÷ shares of ¥1,000,000 or more, which no listed Japanese share reaches. It is a filer tagging error (a value entered at the wrong scale, or a share count in thousands), not an extraction error: the values match the filing's XBRL exactly. Flagged rows are still returned, exactly as filed, but are excluded from the yen aggregates here and counted in excluded_positions / excluded_yen so the exclusion is visible.","notes":[{"holder_table":"largest","note_no":"1","text_ja":"（※）同社は当社の株式を保有しておりませんが、同社子会社が当社の株式を保有しております。"}],"notes_note":"The filing's own numbered footnotes to the named policy table, verbatim. The XBRL numbers them (注)1, (注)2 … and gives no link back to a row, so a note is tied to a position only where it names that issuer.","flows":[{"holder_table":"largest","share_class":"listed","issues_increased":1,"acquisition_cost_yen":null,"issues_decreased":1,"sale_proceeds_yen":219000000,"entity_scope":"largest_holding_company","share_scope":"listed"},{"holder_table":"largest","share_class":"unlisted","issues_increased":null,"acquisition_cost_yen":null,"issues_decreased":null,"sale_proceeds_yen":null,"entity_scope":"largest_holding_company","share_scope":"unlisted"}],"flows_note":"The filer's own tally, as filed, of how many issues increased or decreased during the year and the yen involved — acquisition cost for increases, sale proceeds for decreases. Read against the reclassification table this separates what was actually sold from what merely changed category. Counts are as filed and are not corrected for filer tagging errors.","no_reduction_measure":"This product holds sale proceeds (売却価額), as filed, for one fiscal year. It does NOT hold a book-value-reduction measure. The two are different measures and must never be presented as equivalent.","scale":{"policy_total_yen":2820000000,"listed_yen":2265000000,"unlisted_yen":555000000,"listed_issues":10,"unlisted_issues":6,"equity_yen":178556000000,"equity_basis":"ifrs_consolidated_excl_nci","total_assets_yen":359919000000,"assets_basis":"ifrs_consolidated","pct_of_equity":1.5793364546696835,"pct_of_assets":0.783509622998508,"equity_basis_label":"Consolidated equity attributable to owners of the parent (IFRS)","assets_basis_label":"Consolidated total equity (IFRS)","equity_calc":"total policy shareholdings ÷ shareholders' equity × 100, both as filed in this annual securities report","assets_calc":"total policy shareholdings ÷ total assets × 100, both as filed in this annual securities report"},"scale_entities":[{"holder_table":"reporting","share_class":"listed","book_value_yen":236000000,"issue_count":1,"holder_table_label":"The filer itself","entity_scope":"parent_only","share_scope":"listed"},{"holder_table":"reporting","share_class":"unlisted","book_value_yen":400000000,"issue_count":1,"holder_table_label":"The filer itself","entity_scope":"parent_only","share_scope":"unlisted"},{"holder_table":"largest","share_class":"listed","book_value_yen":2029000000,"issue_count":9,"holder_table_label":"Largest holder in the group","entity_scope":"largest_holding_company","share_scope":"listed"},{"holder_table":"largest","share_class":"unlisted","book_value_yen":155000000,"issue_count":5,"holder_table_label":"Largest holder in the group","entity_scope":"largest_holding_company","share_scope":"unlisted"}],"scale_history":[{"year":"2022","period_end":"2022-03-31","policy_total_yen":5413000000,"equity_yen":190067000000,"equity_basis":"ifrs_consolidated_excl_nci","pct_of_equity":2.8479430937511507,"pct_of_assets":1.5487751143054975},{"year":"2023","period_end":"2023-03-31","policy_total_yen":5767000000,"equity_yen":201643000000,"equity_basis":"ifrs_consolidated_excl_nci","pct_of_equity":2.8600050584448753,"pct_of_assets":1.5836228083423722},{"year":"2024","period_end":"2024-03-31","policy_total_yen":7227000000,"equity_yen":212662000000,"equity_basis":"ifrs_consolidated_excl_nci","pct_of_equity":3.3983504340220634,"pct_of_assets":1.8917659623479153},{"year":"2025","period_end":"2025-03-31","policy_total_yen":2482000000,"equity_yen":173854000000,"equity_basis":"ifrs_consolidated_excl_nci","pct_of_equity":1.4276346819745303,"pct_of_assets":0.6998982017522835},{"year":"2026","period_end":"2026-03-31","policy_total_yen":2820000000,"equity_yen":178556000000,"equity_basis":"ifrs_consolidated_excl_nci","pct_of_equity":1.5793364546696835,"pct_of_assets":0.783509622998508}],"scale_note":"The policy total is Official (as filed) — the filing's own total carrying amount for the whole policy bucket, listed and unlisted, summed across the entities the filing discloses. It is a floor: holdings at group companies the filing does not name are disclosed nowhere and are not included. The percentages are calculated, not filed, and carry their formula. equity_basis names which figure the denominator is, because filers report under Japanese, IFRS or US accounting standards and an adopter of the latter two stops tagging the Japanese consolidated figure — a parent-only denominator is a different measure and is labelled as one, never silently mixed with a group figure. Percentages are null where equity or total assets is missing or not positive; missing is never shown as zero.","scale_reference":"ISS's Japan proxy voting guidelines recommend a vote against the top executive at a company that allocates 20 percent or more of its net assets to cross-shareholdings, a policy effective from February 2022. ISS counts unilateral holdings, not only mutual ones.","ownership_calc":"shares held ÷ (issuer's issued shares − treasury shares) × 100, both as filed, the denominator taken from the issuer's own annual securities report nearest the holding's fiscal year end","ownership_note":"Derived, not filed. The denominator is the issuer's own reported issued shares less treasury shares, from its annual report nearest this holding's fiscal year end on either side — pct_basis_period_end gives that date, and it can fall after the holding's date where that report is the closer one. For a single-class listed stock this equals the stake's share of market capitalisation. It is null where the issuer files no annual report we hold; where the issuer's share count moves by half or more across the window, because a split or issue makes the share base indeterminate; and where the result would exceed 100%, which is a data fault rather than a stake. It is less exact where the issuer has more than one share class (pct_share_classes > 1), because treasury shares are reported across all classes.","holder_share_calc":"this position's book value ÷ the holder's shareholders' equity (or total assets) × 100, both as filed in the holder's own annual securities report","holder_share_note":"The mirror of pct_outstanding. That sizes a stake against the ISSUER — how much of the issuer this holder owns. pct_of_holder_equity and pct_of_holder_assets size the same position against the HOLDER: how much of its own capital is committed to this one name. Calculated, not filed. Null where the holder's filing gives no usable denominator, never zero. holder_equity_basis says which accounting figure the denominator is, and a parent_only basis is not comparable with a consolidated one. A position CAN legitimately exceed 100% of equity — a holder whose book equity is smaller than one long-held stake is a real and commercially interesting case, not an error — so no ceiling is imposed. Extreme values are worth checking against the filing: where the position's own two filed numbers are mutually impossible the row is marked `implausible`, but that test catches only scale errors visible per share, so it does not catch every bad figure. The book value and share count are returned alongside so the reader can check.","action_calc":"keyword match over the filing's own stated purpose and table footnotes: 株式分割、株式併合、株式交換、株式移転、会社分割、合併、持株会社、商号変更、公開買付、上場廃止","ratio_calc":"current shares ÷ prior shares where that ratio is an exact whole number (or its exact reciprocal) — the signature of a split or a consolidation rather than a trade","history":[{"year":"2022","period_end":"2022-03-31","named_holdings":13,"book_value_yen":5259000000},{"year":"2023","period_end":"2023-03-31","named_holdings":13,"book_value_yen":5610000000},{"year":"2024","period_end":"2024-03-31","named_holdings":14,"book_value_yen":7072000000},{"year":"2025","period_end":"2025-03-31","named_holdings":14,"book_value_yen":2327000000},{"year":"2026","period_end":"2026-03-31","named_holdings":11,"book_value_yen":2666000000}],"history_note":"One point per annual report filed. Each year's book value is as filed; book values are fair-valued at period end, so a change reflects both trading and market moves.","provenance":{"trust":"official","note":"Figures exactly as filed in each company's 有価証券報告書 (annual securities report), EDINET. Raw filings archived with SHA-256; doc_id links to the source filing."}}